|Title||The Utility of Liquid Biopsy in Central Nervous System Malignancies.|
|Publication Type||Journal Article|
|Year of Publication||2018|
|Authors||Nevel KS, Wilcox JA, Robell LJ, Umemura Y|
|Journal||Curr Oncol Rep|
|Date Published||2018 06 06|
|Keywords||Biomarkers, Tumor, Central Nervous System Neoplasms, Circulating MicroRNA, Circulating Tumor DNA, Humans, Liquid Biopsy, Meningeal Neoplasms, Neoplasm Metastasis, Neoplastic Cells, Circulating|
PURPOSE OF REVIEW: Liquid biopsy is a sampling of tumor cells or tumor nucleotides from biofluids. This review explores the roles of liquid biopsy for evaluation and management of patients with primary and metastatic CNS malignancies.
RECENT FINDINGS: Circulating tumor cell (CTC) detection has emerged as a relatively sensitive and specific tool for diagnosing leptomeningeal metastases. Circulating tumor DNA (ctDNA) detection can effectively demonstrate genetic markup of CNS tumors in the cerebrospinal fluid, though its role in managing CNS malignancies is less well-defined. The value of micro RNA (miRNA) detection in CNS malignancies is unclear at this time. Current standard clinical tools for the diagnosis and monitoring of CNS malignancies have limitations, and liquid biopsy may help address clinical practice and knowledge gaps. Liquid biopsy offers exciting potential for the diagnosis, prognosis, and treatment of CNS malignancies, but each modality needs to be studied in large prospective trials to better define their use.
|Alternate Journal||Curr Oncol Rep|